Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Fong

Showing results (51-60 of 198) with videos related to

Pageof 20
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancerEric J Small, N Simon Tchekmedyian, Brian I Rini, et al.
The Journal of Urology|October 16, 2007
Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcomeCharles J Ryan, Vivian Weinberg, Jonathan Rosenberg, et al.
Oncoimmunology|December 15, 2018
Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancerKatsunobu Hagihara, Stephen Chan, Li Zhang, et al.
Journal for Immunotherapy of Cancer|May 8, 2020
Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignanciesJason Cham, Li Zhang, Serena Kwek, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 17, 2025
Expression of Programmed Death-Ligand 1 and Programmed Cell Death-1 Across the Anal Neoplasia Disease Continuum and Association With Survival in Anal CancerSona Chowdhury, Cynthia Gasper, Ann A Lazar, et al.
Frontiers in Immunology|January 30, 2020
TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for CancerTimothy John Looney, Denise Topacio-Hall, Geoffrey Lowman, et al.
Cancer Research|December 30, 2016
Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell RepertoireDavid Y Oh, Jason Cham, Li Zhang, et al.
Cancer Research|May 25, 2016
Clonotypic Diversification of Intratumoral T Cells Following Sipuleucel-T Treatment in Prostate Cancer SubjectsNadeem Sheikh, Jason Cham, Li Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 28, 2008
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockadeMarcella Fassò, Rebecca Waitz, Yafei Hou, et al.
Cancer Immunology Research|September 24, 2020
Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-TLi Zhang, Harini Kandadi, Hai Yang, et al.
Pageof 20

Showing results (51-60 of 198) with videos related to

Sort By:
Pageof 20
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancerEric J Small, N Simon Tchekmedyian, Brian I Rini, et al.
The Journal of Urology|October 16, 2007
Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcomeCharles J Ryan, Vivian Weinberg, Jonathan Rosenberg, et al.
Oncoimmunology|December 15, 2018
Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancerKatsunobu Hagihara, Stephen Chan, Li Zhang, et al.
Journal for Immunotherapy of Cancer|May 8, 2020
Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignanciesJason Cham, Li Zhang, Serena Kwek, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 17, 2025
Expression of Programmed Death-Ligand 1 and Programmed Cell Death-1 Across the Anal Neoplasia Disease Continuum and Association With Survival in Anal CancerSona Chowdhury, Cynthia Gasper, Ann A Lazar, et al.
Frontiers in Immunology|January 30, 2020
TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for CancerTimothy John Looney, Denise Topacio-Hall, Geoffrey Lowman, et al.
Cancer Research|December 30, 2016
Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell RepertoireDavid Y Oh, Jason Cham, Li Zhang, et al.
Cancer Research|May 25, 2016
Clonotypic Diversification of Intratumoral T Cells Following Sipuleucel-T Treatment in Prostate Cancer SubjectsNadeem Sheikh, Jason Cham, Li Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 28, 2008
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockadeMarcella Fassò, Rebecca Waitz, Yafei Hou, et al.
Cancer Immunology Research|September 24, 2020
Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-TLi Zhang, Harini Kandadi, Hai Yang, et al.
Pageof 20